The recent discovery of a simple method for making induced pluripotent stem cells (iPSC) from human somatic cells was a major scientific advancement that opened the way for many promising new developments in the study of developmental and degenerative diseases. iPSC have already been used to model many different types of neurological diseases, including autism, schizophrenia, Alzheimer's disease and Parkinson's disease. Because of their pluripotent property, iPSC offer the possibility of modeling human development in vitro. Their differentiation seems to follow the developmental timeline and obeys environmental cues. Clinically relevant phenotypes of neurodegenerative pathologies have also been observed using iPSC derived human neuronal cultures. Options for treatment are still some way off. Although some early research in mouse models has been encouraging, major obstacles remain for neural stem cell (NSC) transplantation therapy. However, iPSC now offer the prospect of an unlimited amount of human neurons or astrocytes for drug testing. The aim of this review is to summarize the recent progress in modeling neural development and neurological diseases using iPSC and to describe their applications for aging research and personalized medicine.
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Introduction
The recent discovery of a simple method for making induced pluripotent stem cells (iPSC) from somatic cells was a major scientific advancement that opened the way for many promising new developments in the study of human developmental and degenerative diseases. Sir John Gordon and Shinya Yamanaka have just been awarded the Nobel Prize in 2012 for Medicine for their contribution to the reprogramming technology, highlighting the significance of this scientific breakthrough. Since the publication of Dr. Yamanaka's work on generation of induced pluripotent stem cells (iPSC), significant progress has already been made as human iPSCs have been used to model many different types of neurological diseases, including autism, schizophrenia, Alzheimer's disease and Parkinson's disease. The aim of this review is to summarize the recent progress in neurological disease modeling using iPSC and to describe their applications and implications in aging research. We will first describe the current methodology for generating neurons, then we will discuss the different in vitro systems attempting to model neurodevelopmental and neurodegenerative diseases. We will also cover how these models could be applied in replacement therapy and medicinal drug development.
There is more than one way to derive human neurons
Currently, there are three different methods to derive neurons from somatic cells. Somatic cells such as skin fibroblasts can be reprogrammed to become iPSC and then differentiated into neurons and glia. They can also be transdifferentiated to become induced neural stem cells (iNSC), or directly transdifferentiated to become induced neurons (iN). It is useful to understand the potentials and limitations for each of these three methods, for their inherent properties and downstream applications are quite different. In this section, we will discuss these three different methods.
Generation of induced pluripotent stem cells (iPSC) from human somatic cells
The generation of iPSC was first developed by Yamanaka's group. They performed a screen of 24 candidate genes, based on the hypothesis that these genes controlled embryonic stem cell identity. They narrowed the candidates down to four factors, Oct3/4, Sox2, Klf4 and c-Myc. When these factors were introduced to mouse embryonic fibroblasts (MEF) with virus, the MEFs were reprogrammed to iPSCs (Takahashi and Yamanaka, 2006) . The cells were morphologically similar to the mouse embryonic stem cells and exhibited pluripotent stem cell markers, SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. The pluripotent potential of the iPSC was tested by teratoma assays, which showed that the iPSC can differentiate to
